AstraZeneca PLC ADR (AZN)

66.86
+0.05(+0.07%)
  • Volume:
    4,096,877
  • Day's Range:
    66.51 - 67.16
  • 52 wk Range:
    53.63 - 71.70

AZN Overview

Prev. Close
66.81
Day's Range
66.51-67.16
Revenue
41.49B
Open
66.74
52 wk Range
53.63-71.7
EPS
-0.33
Volume
4,096,877
Market Cap
206.04B
Dividend (Yield)
1.405
(2.10%)
Average Volume (3m)
7,223,268
P/E Ratio
-
Beta
0.47
1-Year Change
17.4%
Shares Outstanding
1,549,464,013
Next Earnings Date
27 Jul 2022
What is your sentiment on AstraZeneca ADR?
or
Vote to see community's results!

AstraZeneca PLC ADR News

  • AstraZeneca Tops Q1 EPS by $1.06
    • ByInvesting.com-

    AstraZeneca (NASDAQ:AZN) reported Q1 EPS of $1.89, $1.06 better than the analyst estimate of $0.83. Revenue for the quarter came in at $11.4 billion versus the consensus estimate...

  • AstraZeneca ADR Earnings, Revenue beat in Q1
    • ByInvesting.com-

    Investing.com - AstraZeneca (NASDAQ:AZN) ADR reported on Friday first quarter earnings that beat analysts' forecasts and revenue that topped expectations. AstraZeneca ADR...

AstraZeneca PLC ADR Analysis

AstraZeneca PLC ADR Company Profile

AstraZeneca PLC ADR Company Profile

Employees
83100

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company’s marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsSellBuyStrong BuyStrong BuyStrong Buy
SummaryNeutralBuyStrong BuyStrong BuyStrong Buy
  • Thanks you AstraZ. Bullish. management services.
    0
    • 54 to 64 bullish sentiments again volatility trading
      0
      • $68 in 1 month
        4
        • Do you this will grow as EU has approved their Covid vaccine?
          0
          • will reach 100 in 6 months time
            0
            • I think the vaccine is nothing next to the antibody coctail, known as AZD7442 that Astra is working on at the momenthttps://www.reuters.com/article/health-coronavirus-astrazeneca-antibody-idUSKBN28100E
              0
              • Good buy in the long term.
                1
                • https://www.wsj.com/articles/astrazeneca-agrees-to-buy-alexion-for-39-billion-11607778687?redirect=amp#click=https://t.co/EeYlRyEn3g
                  0
                  • I expect it to reach $ 100 next month
                    1
                    • for super rich returns
                      0